Skin patch T-cell Covid vaccine to be trialled in Switzerland
The new vaccine will be administered as a tiny skin patch bristling with micro-needles that release the shot within seconds.
Keystone / Alexandra Wey
A British biotech firm is set to start clinical trials in Switzerland of a skin patch vaccine against Covid-19 that uses T-cells and could offer longer-lasting immunity than existing vaccines.
This content was published on
2 minutes
The Guardian/swissinfo/sb
Español
es
Suiza someterá a prueba vacuna COVID en parche cutáneo
Emergex announcedExternal link on Monday that it had received the green light from the Swiss drugs regulator to carry out initial human trials in Lausanne, starting January 3, 2022.
The company’s easy-to-administer skin patch vaccine primes T-cells – a group of immune cells that can target and destroy virus-infected cells – to remove infected cells from the body quickly after infection, thus preventing viral replication and disease.
Robin Cohen, Emergex’s chief commercial officer, told The GuardianExternal link newspaper: “This is the first time a regulator has approved a Covid vaccine to go into clinical trials whose sole purpose is to generate a targeted T-cell response in the absence of an antibody response and those T-cells look for infected cells and kill them.”
Current Covid-19 vaccines mainly generate an antibody response that wanes over time, which means people need booster shots to maintain protection against the virus. The Emergex vaccine works differently, by killing infected cells quickly. This means it could offer longer-lasting immunity – possibly for decades – and could also be better at fighting virus mutations, said Cohen.
The trial will be conducted by Blaise Genton, a professor at the University of Lausanne’s centre for primary care and public health. He said: “This exciting new scientific approach to developing a vaccine against Sars-CoV-2 addresses the need to generate a T-cell response to elicit long-term immunity.”
In all, 26 people will receive a high and a low dose of its experimental Covid-19 vaccine. Interim results from the trial are expected in June.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Have you heard something about Swiss diplomacy that you’d like us to fact check?
Not all information circulating about Switzerland’s foreign relations is accurate or well understood. Tell us what you'd like us to fact check or clarify.
WEF: Trump to speak virtually, Zelensky to appear in person
This content was published on
US President-elect Donald Trump will attend this year's annual meeting of the World Economic Forum (WEF) in Davos via video conference. He is scheduled to speak on January 23.
Coop washes its hands of The Body Shop in Switzerland
This content was published on
The Body Shop is facing closure in Switzerland. Retailer Coop is no longer extending the franchise agreement for its cosmetics subsidiary.
Three out of ten Ukrainian refugees in Switzerland have a job
This content was published on
More and more refugees from Ukraine have a job in Switzerland. The employment rate of people with protection status S was just under 30% at the end of 2024.
Swiss private companies invest CHF18 billion in research
This content was published on
In 2023, private companies in Switzerland spent CHF18 billion ($19.7 billion) on their own research and development. This is CHF1.2 billion more than in 2021.
This content was published on
Lindt & Sprüngli grew strongly in 2024. The Swiss chocolate manufacturer is also aiming for above-average growth in the current financial year.
‘Surprisingly few’ signatures invalid for ban on animal testing
This content was published on
The initiative to ban animal testing was submitted in November with around 127,600 signatures. "Surprisingly few" signatures are not valid, the initiative's organisers have now said.
Geneva hosts Iran nuclear talks before return of Trump
This content was published on
Iran and the main European powers began two days of talks in Geneva on Iran's nuclear programme on Monday, a week ahead of Donald Trump's inauguration as US president.
While Switzerland struggles to vaccinate, Portugal is already finished
This content was published on
Nowhere are more people vaccinated against Covid-19 than in Portugal, where 98% of over 25-year-olds have had both doses.
Vaccine alternative has limited impact on Covid campaign
This content was published on
The offer of a non-mRNA Covid vaccine in Switzerland has failed to speed up the government’s vaccination campaign, experts say.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.